Matching articles for "Omlyclo"
In Brief: Omlyclo — An Omalizumab Biosimilar Interchangeable with Xolair
The Medical Letter on Drugs and Therapeutics • June 9, 2025; (Issue 1730)
Omlyclo (omalizumab-igec; Celltrion), a biosimilar
product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair, has been approved by
the FDA for same indications as Xolair (see Table...
Omlyclo (omalizumab-igec; Celltrion), a biosimilar
product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair, has been approved by
the FDA for same indications as Xolair (see Table 1).
Omlyclo is the first Xolair biosimilar to be approved in
the US.
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).